Atea Pharmaceuticals (AVIR) Expected to Announce Earnings on Wednesday

Atea Pharmaceuticals (NASDAQ:AVIR) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Atea Pharmaceuticals Stock Down 1.6 %

AVIR opened at $3.09 on Monday. The business has a fifty day moving average of $3.19 and a 200 day moving average of $3.38. Atea Pharmaceuticals has a 52-week low of $2.75 and a 52-week high of $4.60. The stock has a market cap of $260.98 million, a P/E ratio of -1.49 and a beta of 0.19.

Insider Activity at Atea Pharmaceuticals

In related news, Director Franklin M. Berger sold 359,606 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the transaction, the director now owns 451,897 shares in the company, valued at $1,287,906.45. The trade was a 44.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 17.80% of the stock is owned by company insiders.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.